Streamlining Success: The need for automated systems to accelerate Cell Line Development

In the process of cell line development (CLD), clone screening is a crucial bottleneck in the process of identifying optimal cell lines to produce monoclonal antibodies and recombinant proteins. The aim of cell line development in biotherapeutics production is to obtain high-yielding clones that produce high-yield high-quality monoclonal antibodies. However, current cell line screening workflows face bottlenecks due to their complexity, number of screening parameters, intense resource utilization, and other challenges.

Clone generation results in the production of too many candidate cell lines to be able to effectively screen manually in a timely and reliable manner. Even with faster titer assessment workflows and growth and metabolic assays, the sheer number of assays and readouts generated during the process of comprehensively screening clones can be overwhelming. The potential for overlooking a promising clone because of manual error or incomplete data is too great to risk. Bringing comprehensive, purpose-built automation into clone screening can help mitigate many of the challenges in clone screening., Advanced automation systems will combine a liquid handling workstation and multiple analytical equipment, such as screening and cell viability technologies into a single, advanced, standalone platform. Typical cell line development processes, such as cell culture via automated passaging, bioreactor studies to understand and deliver optimal growth conditions, automated titer assessment to maximize productivity, and automated cell counts to obtain precise measurements, should be incorporated into these systems, allowing scientists to find the most vigorous growers while simultaneously having low sample volume requirements. These fully automated cell culture and clone ranking systems should increase throughput, reduce selection risks and reduce manual laboratory work by a significant amount - even by up to >90%. Of course, software should also provide accessible, early insights via continuous measurements throughout the entire cultivation process, enabling timely decision-making regarding the best clones.

The need to improve cell line development efficiency and consistency as part of the quest to find biotherapeutics faster is greater than ever today. At the Life Sciences companies of Danaher, we adopt a holistic approach to drug discovery and analytics to meet your throughput needs, automating and enhancing workflows to unlock productivity and improve quality. To learn more about our solutions or explore ways of partnering with us, contact an expert at the Life Sciences companies of Danaher today.